These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30821926)

  • 21. Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort.
    Golder V; Kandane-Rathnayake R; Hoi AY; Huq M; Louthrenoo W; An Y; Li ZG; Luo SF; Sockalingam S; Lau CS; Lee AL; Mok MY; Lateef A; Franklyn K; Morton S; Navarra ST; Zamora L; Wu YJ; Hamijoyo L; Chan M; O'Neill S; Goldblatt F; Morand EF; Nikpour M;
    Arthritis Res Ther; 2016 Nov; 18(1):260. PubMed ID: 27829463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
    Ugarte-Gil MF; Hanly J; Urowitz M; Gordon C; Bae SC; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Ramsey-Goldman R; Manzi S; Jönsen A; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Lim S; Inanc M; Kalunian K; Jacobsen S; Peschken C; Kamen DL; Askanase A; Pons-Estel BA; Alarcón GS
    Ann Rheum Dis; 2022 Nov; 81(11):1541-1548. PubMed ID: 35944946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
    Pitsigavdaki S; Nikoloudaki M; Garantziotis P; Silvagni E; Repa A; Marangoni A; Flouri I; Avgoustidis N; Parperis K; Fanouriakis A; Govoni M; Sidiropoulos P; Boumpas DT; Bortoluzzi A; Bertsias G
    Ann Rheum Dis; 2024 Mar; 83(4):464-474. PubMed ID: 38233103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State In Patients With Newly Diagnosed Versus Established Systemic Lupus Erythematosus.
    Golder V; Kandane-Rathnayake R; Louthrenoo W; Chen YH; Cho J; Lateef A; Hamijoyo L; Luo SF; Wu YJ; Navarra SV; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake BMDB; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Lau CS; Nikpour M; Hoi A; Morand EF;
    J Rheumatol; 2024 May; ():. PubMed ID: 38490668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low disease activity state in juvenile-onset systemic lupus erythematosus.
    Ozturk K; Caglayan S; Tanatar A; Baglan E; Yener Otar G; Kavrul Kayaalp G; Karadag SG; Demir F; Sonmez HE; Ozdel S; Cakan M; Aktay Ayaz N; Sozeri B;
    Lupus; 2021 Nov; 30(13):2144-2150. PubMed ID: 34723709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
    Petri M; Magder LS
    Arthritis Rheumatol; 2018 Nov; 70(11):1790-1795. PubMed ID: 29806142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study.
    Connelly K; Kandane-Rathnayake R; Hoi A; Louthrenoo W; Hamijoyo L; Cho J; Lateef A; Fen Luo S; Wu YJ; Li Z; Navarra S; Zamora L; Sockalingam S; Hao Y; Zhang Z; Katsumata Y; Harigai M; Oon S; Chan M; Chen YH; Bae SC; O'Neill S; Goldblatt F; Kikuchi J; Takeuchi T; Ling Ng KP; Tugnet N; Basnayake BMDB; Ohkubo N; Tanaka Y; Sing Lau C; Nikpour M; Golder V; Morand EF;
    Lancet Rheumatol; 2022 Dec; 4(12):e831-e841. PubMed ID: 38261391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus.
    Nived O; Jönsen A; Bengtsson AA; Bengtsson C; Sturfelt G
    J Rheumatol; 2002 Jul; 29(7):1398-400. PubMed ID: 12136895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study.
    Kandane-Rathnayake R; Louthrenoo W; Hoi A; Luo SF; Wu YJ; Chen YH; Cho J; Lateef A; Hamijoyo L; Navarra SV; Zamora L; Sockalingam S; An Y; Li Z; Katsumata Y; Harigai M; Hao Y; Zhang Z; Kikuchi J; Takeuchi T; Basnayake BMDB; Chan M; Ng KPL; Tugnet N; Kumar S; Oon S; Goldblatt F; O'Neill S; Gibson KA; Ohkubo N; Tanaka Y; Bae SC; Lau CS; Nikpour M; Golder V; Morand EF;
    Arthritis Res Ther; 2022 Mar; 24(1):70. PubMed ID: 35287720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS).
    Abdelhady EI; Rabie M; Hassan RA
    Clin Rheumatol; 2021 Nov; 40(11):4553-4558. PubMed ID: 34142298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LUPUS-BEST-treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial.
    Mucke J; Kuss O; Brinks R; Schanze S; Schneider M
    Lupus Sci Med; 2021 Jul; 8(1):. PubMed ID: 34253649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Determinant Factors of Morbidity in Patients with Systemic Lupus Erythematosus].
    Jacinto M; Silva E; Riso N; Moraes-Fontes MF
    Acta Med Port; 2017 May; 30(5):368-372. PubMed ID: 28865500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity.
    Babaoğlu H; Li J; Goldman D; Magder LS; Petri M
    Arthritis Care Res (Hoboken); 2020 Feb; 72(2):225-232. PubMed ID: 31507071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes.
    Pawlak-Buś K; Schmidt W; Leszczyński P
    Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):949-959. PubMed ID: 36808341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).
    Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Catoggio LJ; Drenkard C; Sarano J; Berbotto GA; Borba EF; Sato EI; Tavares Brenol JC; Uribe O; Ramirez Gómez LA; Guibert-Toledano M; Massardo L; Cardiel MH; Silveira LH; Chacón-Diaz R; Alarcón GS; Pons-Estel BA;
    Ann Rheum Dis; 2017 Dec; 76(12):2071-2074. PubMed ID: 28939626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women.
    Fernández M; Calvo-Alén J; Alarcón GS; Roseman JM; Bastian HM; Fessler BJ; McGwin G; Vilá LM; Sanchez ML; Reveille JD
    Arthritis Rheum; 2005 Jun; 52(6):1655-64. PubMed ID: 15934092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of predominant Lupus Low Disease Activity State (LLDAS-50).
    Babaoglu H; Li J; Goldman D; Magder LS; Petri M
    Lupus; 2019 Dec; 28(14):1648-1655. PubMed ID: 31694446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chinese Systemic Lupus Erythematosus Treatment and Research Group (CSTAR) Registry XI: gender impact on long-term outcomes.
    Zhang S; Ye Z; Li C; Li Z; Li X; Wu L; Liu S; Zuo X; Zhu P; Wang Z; Wang Y; Wang Z; Zhao J; Wang Q; Tian X; Li M; Zeng X
    Lupus; 2019 Apr; 28(5):635-641. PubMed ID: 30939980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus.
    Gao D; Hao Y; Mu L; Xie W; Fan Y; Ji L; Zhang Z
    Rheumatology (Oxford); 2020 Nov; 59(11):3400-3407. PubMed ID: 32337549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study.
    Golder V; Huq M; Franklyn K; Calderone A; Lateef A; Lau CS; Lee ALH; Navarra STV; Godfrey T; Oon S; Hoi AYB; Morand EF; Nikpour M
    Semin Arthritis Rheum; 2017 Jun; 46(6):798-803. PubMed ID: 28216192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.